Full Press Release Details
MindMed Bolsters Management Team, Appoints Peter
Mack PhD as Vice President of Pharmaceutical Development
New York, NY - May 13, 2021 - MindMed (NASDAQ: MNMD, NEO: MMED, DE:
MMQ), a leading psychedelic-inspired medicine company has appointed Peter Mack PhD as Vice President of Pharmaceutical Development.
As MindMed progresses it's Discover and Develop efforts for multiple
commercial clinical programs including LSD and an ibogaine derivative, 18-MC, Peter will lead MindMed's product development activities
across its entire portfolio of investigational drugs. In addition, Peter will oversee partnerships with Contract Manufacturing Development
Organizations and other discovery efforts to support the advancement of MindMed's proprietary new chemical entities.
Peter joins MindMed from AstraZeneca, where he was the Director of
Manufacturing for Inhalation Product Development. Peter previously worked at Pearl Therapeutics (acquired by AstraZeneca in 2013) where
he helped pioneer the pharmaceutical development of inhaled combination therapies for highly prevalent respiratory diseases.
Peter holds a dual PhD in Medical Engineering / Medical Physics from
Harvard Medical School and Massachusetts Institute of Technology (MIT), where he was a National Institute of Health (NIH) Biomechanics
Training Grant Recipient. Peter also holds a Masters of Science in Mechanical Engineering from MIT. During his time in academia and the
pharmaceutical industry, Peter contributed to numerous peer reviewed articles and patents.
"MindMed is constantly on the hunt to find the best people to
help us shape the future of psychedelic medicine from discovery to delivery. We are excited to have Peter join us on our mission and help
us craft a world class pharmaceutical development organization," said J.R. Rahn, Chief Executive Officer and Co-founder of MindMed.
MindMed is a clinical-stage psychedelic medicine biotech company that
discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling
a compelling drug development pipeline of innovative treatments based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and
an Ibogaine derivative, 18-MC. The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to
developing the next generation of psychedelic inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian
NEO exchange under the symbol MMED. MindMed is also traded in Germany under the symbol MMQ.
Forward-Looking Statements
Certain statements in this news release related
to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective
in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future
events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words
such as "will", "may", "should", "could", "intend", "estimate", "plan",
"anticipate", "expect", "believe", "potential" or "continue", or the negative thereof
or similar variations. Forward-looking information in this news release include, but are not limited to, statements regarding the duration
of patent protections for NCE tryptamine and whether such protections will extend beyond the FDA-granted NCE exclusivity period and the
impact that NCE tryptamine will have on the Company's future pipeline. Although the Company believes that the expectations reflected
in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be
placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or
achievements of the Company. There are numerous risks and uncertainties that could cause actual results and the Company's plans
and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows;
limited operating history; incurrence of future losses; availability of additional capital; lack of product revenue; compliance with laws
and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory
scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines
industry; as well as those risk factors discussed or referred to herein and the risks described under the headings "Risk Factors"
in the Company's filings with the securities regulatory authorities in all provinces and territories of Canada which are available
under the Company's profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange
Commission on EDGAR at www.sec.gov. Should one or more of these risks or uncertainties materialize,
or should assumptions underlying the forward-looking information prove incorrect, actual results and future events could differ materially
from those anticipated in such information. Although the Company has attempted to identify important risks, uncertainties and factors
that could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended.
These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they
are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend and does
not assume any obligation to update this forward-looking information.
Media Contact: mindmed@150bond.com